Olmesartan Medoxomil (Votum)

An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.

Also Known As:

Votum; Benicar; Olmetec; 5-Methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate - T287346; CS 866; CS-866; CS866; Medoxomil, Olmesartan

Networked: 257 relevant articles (55 outcomes, 112 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - Olmesartan Medoxomil: 257
        Olmesartan Medoxomil Drug Combination Amlodipine Besylate: 7
    - Tetrazoles: 14
      - Olmesartan Medoxomil: 257
        Olmesartan Medoxomil Drug Combination Amlodipine Besylate: 7

Experts

1.	Neutel, Joel M: 16 articles (09/2017 - 09/2002)
2.	Oparil, Suzanne: 13 articles (01/2020 - 03/2007)
3.	Chrysant, Steven G: 13 articles (01/2014 - 06/2006)
4.	Kereiakes, Dean J: 13 articles (01/2014 - 01/2007)
5.	Volpe, Massimo: 12 articles (05/2021 - 01/2009)
6.	Dubiel, Robert: 12 articles (10/2012 - 01/2005)
7.	Shojaee, Ali: 11 articles (04/2013 - 08/2009)
8.	Lee, James: 10 articles (04/2016 - 04/2008)
9.	Izzo, Joseph L: 9 articles (01/2014 - 09/2002)
10.	Melino, Michael: 9 articles (01/2014 - 04/2008)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2007 - "In an integrated analysis of seven US and European randomized, placebo-controlled, dose-ranging trials involving 3055 patients with stage 2 hypertension treated with olmesartan medoxomil 2.5-80 mg/day or placebo for 8 weeks, all olmesartan medoxomil doses were significantly more effective than placebo in lowering the mean DBP and mean SBP (p<or=0.001); notably, optimal BP-lowering efficacy was observed at higher dosages. " 10/01/2004 - "These facts suggest that olmesartan medoxomil would be beneficial for the treatment of hypertension and other end-organ diseases." 04/01/2003 - "Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. " 09/01/2002 - "Olmesartan medoxomil appears to be a safe and effective once-a-day treatment for hypertension." 04/19/2001 - "The data show that CS-866 is effective and safe for the treatment of hypertension. "
2.	Essential Hypertension 06/01/2001 - "Olmesartan medoxomil was safe and highly effective in lowering blood pressure in patients with mild to moderate essential hypertension in these studies." 10/01/2012 - "To evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension using different methods according to ambulatory blood pressure monitoring. " 10/01/2012 - "Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring." 01/01/2007 - "Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study." 09/01/2002 - "In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension. "
3.	Type 2 Diabetes Mellitus (MODY) 09/01/2011 - "Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus." 04/01/2016 - "Two studies (ROADMAP and ORIENT) evaluating the renoprotective effects of olmesartan medoxomil (OM) in patients with type 2 diabetes suggested OM is associated with increased cardiovascular mortality. " 01/01/2011 - "The current preliminary study showed that olmesartan medoxomil treatment might decrease plasma BNP levels, independent of its BP-lowering effect, in hypertensive patients with type 2 diabetes." 01/01/2011 - "The objective of this study was to determine the effects of olmesartan medoxomil, a novel ARB, on the plasma level of BNP in hypertensive patients with type 2 diabetes. " 02/01/2006 - "A total of 4400 type 2 diabetes patients with normoalbuminuria will be randomized to treatment with 40 mg of olmesartan medoxomil once daily or placebo. "
4.	Atherosclerosis 01/01/2006 - "Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence." 04/19/2001 - "CS-866 was also tested in the Watanabe heritable hyperlipidemic (WHHL) rabbit model of atherosclerosis. " 01/01/2006 - "The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes." 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis. " 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis."
5.	Diabetic Nephropathies (Diabetic Nephropathy) 01/01/2005 - "Our study suggests that olmesartan medoxomil could be a valuable drug for the treatment of diabetic nephropathy by blocking the deleterious effects of AGEs." 10/01/2002 - "In electron microscopic analysis, loss of glomerular anionic sites, one of the causes of glomerular hyperpermeability in diabetic nephropathy, was found to be significantly prevented by CS-866 treatment. " 01/01/2003 - "Additionally, animal studies indicate that olmesartan medoxomil may prove to be useful treatment for diabetic nephropathy, as well as atherosclerosis. " 04/19/2001 - "On the basis of results from animal models, CS-866 may be a useful treatment for diabetic nephropathy and atherosclerosis." 04/19/2001 - "Given the proposed involvement of the renin-angiotensin system in diabetic nephropathy and atherosclerosis, we have tested CS-866 in animal models of these conditions. "

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	Hydrochlorothiazide (Esidrix)
3.	Antihypertensive Agents (Antihypertensives)
4.	Angiotensin Receptor Antagonists
5.	olmesartan
6.	Ramipril (Altace)
7.	Losartan (Cozaar)
8.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
9.	Angiotensin II
10.	Calcium Channel Blockers (Blockers, Calcium Channel)

Related Therapies and Procedures

1.	Therapeutics
2.	Sodium-Restricted Diet (Diet, Sodium Restricted)
3.	Oral Administration
4.	Drug Therapy (Chemotherapy)
5.	Peritoneal Dialysis